Researcher Spotlight: Reid Merryman, MD, MS Dana-FArber Cancer Institute Classical Hodgkin lymphoma (cHL) tumor cells have developed several ways to avoid detection and destruction by the immune system, including expression of immune checkpoint proteins on their surface to shield them…
Researcher Spotlight: Xu Cao, PhD City of Hope and Beckman Research Institute Many types of non-Hodgkin lymphoma (NHL) remain incurable due to its intrinsic genomic instability facilitating the escape from cytotoxic or targeted therapies. “Recent breakthroughs in understanding macrophage-mediated immune…
Researcher Spotlight: Natalie Grover, MD The University of North Carolina at Chapel Hill Although a majority of patients with Hodgkin lymphoma (HL) are cured with first-line therapy; about 15 percent of those patients experience primary refractory disease or relapse after…
Researcher Spotlight: Yong Gu Lee, PhD The Trustees of the University of Pennsylvania Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and is the most common hematologic malignancy in the US. The prognosis…
Researcher Spotlight: Alexia Martinez de Paz, PhD Joan & Sanford I. Weill Medical College of Cornell University Cell-fate transitions (a biological process in which the function of a cell gets specialized, reprogrammed, or altered) during the germinal center (GC) reaction…
Researcher Spotlight: Laurianne Scourzic, PhD Joan & Sanford I. Weill Medical College of Cornell University Many B-cell lymphoma patients are resistant to, or relapse after, treatment. While researchers have demonstrated the causal role of cancer stem cells in the relapsing…
Researcher Spotlight: Paolo Strati, MD University of Texas M.D. Anderson Cancer Center Patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T cells have increased their cure rate from 10 percent to 40 percent.…
Researcher Spotlight: Ryan Lynch, MD University of Washington Checkpoint inhibitors, a type of immunotherapy, have been approved for patients with relapsed Hodgkin lymphoma (HL); however, they do not lead to durable remissions in most patients. Dr. Lynch’s LRF grant project…
Researcher Spotlight: Adam Lin, MD, PhD Northwestern University Feinberg School of Medicine Many immunotherapies and cell therapies on the market have increased the cure rate for patients with non-Hodgkin lymphoma (NHL); however, the percentage of relapse and death continues to…
Researcher Spotlight: Abi Vijenthira, MD University Health Network Lymphoma is the most common blood cancer in Canada, and diffuse large B-cell lymphoma (DLBCL) has the greatest incidence in older patients compared to all other lymphomas. Older patients are at risk…